Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...125126127128129130131132133134135136137»
  • ||||||||||  Trial primary completion date:  MGEX: Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis (clinicaltrials.gov) -  May 16, 2017   
    P=N/A,  N=42, Recruiting, 
    These data suggest a potential new treatment approach for a population of patients with limited treatment options and support the evaluation of nivolumab and nivolumab plus ipilimumab in phase 3 randomised controlled trials in SCLC. Trial primary completion date: Mar 2017 --> Oct 2018
  • ||||||||||  Biomarker, Enrollment change, Trial termination, Trial primary completion date:  Biomarkers in Neural Disorders (clinicaltrials.gov) -  May 9, 2017   
    P=N/A,  N=35, Terminated, 
    Initiation date: Nov 2015 --> Mar 2016 N=270 --> 35 | Recruiting --> Terminated | Trial primary completion date: Jun 2021 --> May 2017
  • ||||||||||  Trial primary completion date:  The Role of the Thymus in Myasthenia Gravis (clinicaltrials.gov) -  Apr 21, 2017   
    P=N/A,  N=80, Active, not recruiting, 
    N=270 --> 35 | Recruiting --> Terminated | Trial primary completion date: Jun 2021 --> May 2017 Trial primary completion date: Dec 2016 --> Dec 2018
  • ||||||||||  bortezomib / Generic mfg.
    Trial primary completion date:  Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) (clinicaltrials.gov) -  Apr 21, 2017   
    P2,  N=18, Recruiting, 
    Trial primary completion date: Dec 2016 --> Dec 2018 Trial primary completion date: Dec 2016 --> Dec 2018
  • ||||||||||  Biomarker, Enrollment open:  Biomarkers in Neural Disorders (clinicaltrials.gov) -  Apr 4, 2017   
    P=N/A,  N=270, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Myasterix (CV-MG01) / CuraVac
    Enrollment closed, Enrollment change, Trial primary completion date, IO biomarker:  Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) -  Mar 21, 2017   
    P1/2,  N=24, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=32 --> 24 | Trial primary completion date: Mar 2017 --> Aug 2017
  • ||||||||||  Enrollment closed:  Tissue Repository for Studies of Myasthenia Gravis (clinicaltrials.gov) -  Mar 7, 2017   
    P=N/A,  N=300, Active, not recruiting, 
    Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Active, not recruiting
  • ||||||||||  Enrollment open, Trial primary completion date:  SAA: Serum Auto-Antibodies in Neurological Diseases (clinicaltrials.gov) -  Feb 23, 2017   
    P=N/A,  N=120, Enrolling by invitation, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Enrolling by invitation | Trial primary completion date: Jun 2015 --> Dec 2020
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial primary completion date:  Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) -  Feb 12, 2017   
    P2,  N=40, Recruiting, 
    This is the first case of postirradiation neuromyotonia to be reported with such extensive cranial nerve and brainstem involvement. Trial primary completion date: Jun 2017 --> Dec 2017
  • ||||||||||  New trial:  OVEMP in Myasthenia (clinicaltrials.gov) -  Feb 10, 2017   
    P=N/A,  N=200, Recruiting, 
  • ||||||||||  Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
    Trial primary completion date:  SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) -  Jan 10, 2017   
    P=N/A,  N=4, Terminated, 
    Enrolling by invitation --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Trial primary completion date:  Exercise for Stable Myasthenia Gravis (clinicaltrials.gov) -  Oct 31, 2016   
    P1,  N=30, Recruiting, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2015 --> Dec 2020
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
    Enrollment change, Trial primary completion date:  Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) -  Jul 27, 2016   
    P3,  N=20, Recruiting, 
    Trial primary completion date: Jul 2016 --> Jun 2017 N=10 --> 20 | Trial primary completion date: May 2016 --> Oct 2017
  • ||||||||||  Trial termination, Trial primary completion date:  Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis (clinicaltrials.gov) -  Jul 19, 2016   
    P1,  N=9, Terminated, 
    Active, not recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2016; No participants enrolled for more than two years. No plan to continue study.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Enrollment closed:  BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis (clinicaltrials.gov) -  May 5, 2016   
    P2,  N=50, Active, not recruiting, 
    N=20 --> 40 Recruiting --> Active, not recruiting
  • ||||||||||  Biomarker, New trial:  Biomarkers in Neural Disorders (clinicaltrials.gov) -  May 4, 2016   
    P=N/A,  N=270, Not yet recruiting, 
  • ||||||||||  Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
    Trial primary completion date:  SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) -  Apr 7, 2016   
    P=N/A,  N=4, Terminated, 
    Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Dec 2016
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
    Enrollment open, Trial initiation date:  Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) -  Jan 26, 2016   
    P3,  N=10, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Jan 2016
  • ||||||||||  Benlysta (belimumab) / GSK
    Trial completion, Enrollment change:  The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) -  Jan 25, 2016   
    P2,  N=40, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Jan 2016 Active, not recruiting --> Completed | N=60 --> 40
  • ||||||||||  Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
    Trial primary completion date:  SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) -  Jan 25, 2016   
    P=N/A,  N=4, Terminated, 
    Active, not recruiting --> Completed | N=60 --> 40 Trial primary completion date: Dec 2015 --> Mar 2016
  • ||||||||||  Trial primary completion date:  The Role of the Thymus in Myasthenia Gravis (clinicaltrials.gov) -  Jan 21, 2016   
    P=N/A,  N=80, Active, not recruiting, 
    Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Dec 2015 --> Dec 2016